Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on bioengineered human tissue development, has scheduled its third quarter 2024 financial results release for November 8, 2024. The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial performance and provide updates on its acellular tissue engineered vessel (ATEV) programs. The presentation will be accessible via phone and webcast, with replay available on the company's investor website for 30 days.
Humacyte (Nasdaq: HUMA), una società biotecnologica in fase clinica focalizzata sullo sviluppo di tessuti umani bioingegnerizzati, ha programmato il rilascio dei suoi risultati finanziari del terzo trimestre 2024 per l'8 novembre 2024. L'azienda organizzerà una call e un webcast alle 8:30 a.m. ET per discutere le performance finanziarie e fornire aggiornamenti sui suoi programmi di vaso ingegnerizzato a tessuto acellulare (ATEV). La presentazione sarà accessibile tramite telefono e webcast, con replay disponibile sul sito web per gli investitori dell'azienda per 30 giorni.
Humacyte (Nasdaq: HUMA), una compañía de biotecnología en etapa clínica centrada en el desarrollo de tejidos humanos bioingenierizados, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el 8 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia y un webcast a las 8:30 a.m. ET para discutir el desempeño financiero y proporcionar actualizaciones sobre sus programas de vasos bioingenierizados sin células (ATEV). La presentación será accesible por teléfono y webcast, con una repetición disponible en el sitio web de inversores de la compañía durante 30 días.
Humacyte (Nasdaq: HUMA)는 생체 공학적 인간 조직 개발에 초점을 맞춘 임상 단계의 생명공학 플랫폼 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 8일로 예정했습니다. 이 회사는 오전 8시 30분 ET에 재무 성과에 대해 논의하고 세포가 없는 조직 공학 혈관(ATEV) 프로그램에 대한 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다. 프레젠테이션은 전화 및 웹캐스트를 통해 접근 가능하며, 회사의 투자자 웹사이트에서 30일 동안 재청취할 수 있습니다.
Humacyte (Nasdaq: HUMA), une société de biotechnologie en phase clinique axée sur le développement de tissus humains bio-ingénierés, a prévu la publication de ses résultats financiers du troisième trimestre 2024 pour le 8 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast à 8h30 ET pour discuter des performances financières et fournir des mises à jour sur ses programmes de vaisseaux biologiquement ingénierés sans cellules (ATEV). La présentation sera accessible par téléphone et webcast, avec un replay disponible sur le site web des investisseurs de l'entreprise pendant 30 jours.
Humacyte (Nasdaq: HUMA), ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entwicklung von bioengineering Menschengewebe konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für den 8. November 2024 angesetzt. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um die finanzielle Leistung zu besprechen und Updates zu seinen zellfreien, gewebetechnischen Gefäßprogrammen (ATEV) bereitzustellen. Die Präsentation wird sowohl telefonisch als auch per Webcast zugänglich sein, mit einer Wiederholung, die für 30 Tage auf der Investorenseite des Unternehmens verfügbar ist.
- None.
- None.
DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2024, on Friday, November 8, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs.
| Title: | Humacyte Third Quarter 2024 Financial Results and Corporate Update |
| Date: | November 8, 2024 |
| Time: | 8:30 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13749485 (Conference ID) |
| Call meTM Feature: | Click Here |
| Webcast: | Webcast Link - Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com. The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) release Q3 2024 earnings?
What time is Humacyte's (HUMA) Q3 2024 earnings call?
What will Humacyte (HUMA) discuss in their Q3 2024 earnings call?
